Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Novartis
BeOne Medicines
Memorial Sloan Kettering Cancer Center
AVM Biotechnology Inc
BeOne Medicines
Genmab
AstraZeneca
Nurix Therapeutics, Inc.
Genmab
Genmab
Vironexis Biotherapeutics Inc.
Medical University of South Carolina
AstraZeneca
Acerta Pharma BV
Dana-Farber Cancer Institute
Sellas Life Sciences Group
Galapagos NV
University of Chicago
Juno Therapeutics, a Subsidiary of Celgene
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Medical College of Wisconsin
BeOne Medicines
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Acerta Pharma BV
Incyte Corporation
AstraZeneca
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
BeOne Medicines
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Acerta Pharma BV
BeOne Medicines
CRISPR Therapeutics
MingSight Pharmaceuticals, Inc
Sichuan Baili Pharmaceutical Co., Ltd.
University of California, San Diego
Genentech, Inc.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Ottawa Hospital Research Institute
M.D. Anderson Cancer Center
University of Utah
Mayo Clinic
IDP Discovery Pharma S.L.
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.